Adaptive Biotechnologies’ stock surged following the National Comprehensive Cancer Network’s updated multiple myeloma guidelines, which now recommend baseline clonotype identification at diagnosis or sample storage for future MRD testing. This change from optional consideration to recommendation is expected to facilitate earlier and more widespread use of Adaptive’s ClonoSeq assay by easing initial diagnostic testing barriers. Analysts view this as a positive development that could drive increased test volume and revenues for Adaptive, particularly in community oncology settings.